## References

1. Rais A, Zarka S, Derazne E, et al. Varicocoele among 1,300,000 Israeli adolescent males: time trends and association with body mass index. Andrology 2013;1:663-9.
2. Clavijo RI, Carrasquillo R, Ramasamy R. Varicoceles: prevalence and pathogenesis in adult men. Fertil Steril 2017;108:364-9.
3. Choyke PL, Glenn GM, Wagner JP, et al. Epididymal cystadenomas in von Hippel-Lindau disease. Urology 1997;49:926-31.
4. Varshney N, Kebede AA, Owusu-Dapaah H, Lather J, Kaushik M, Bhullar JS. A review of Von Hippel-Lindau syndrome. J Kidney Cancer VHL 2017;4:20-9.
5. Le O, Roy A, Silverman PM, Kundra V. Common and uncommon adult unilateral renal masses other than renal cell carcinoma. Cancer Imaging 2012;12:194-204.
6. Choi H, Park JY, Kim JH, Moon du G, Lee JG, Bae JH. Primary renal hydatid cyst: mis-interpretation as a renal malignancy. Korean J Parasitol 2014;52:295-8.
7. Hu SL, Chang A, Perazella MA, Okusa MD, Jaimes EA, Weiss RH. The nephrologist's tumor: basic biology and management of renal cell carcinoma. J Am Soc Nephrol 2016;27:2227-37.
8. Malouf GG, Monzon FA, Couturier J, et al. Genomic heterogeneity of translocation renal cell carcinoma. Clin Cancer Res 2013;19:4673-84.
9. Barr ML, Jilaveanu LB, Camp RL, Adeniran AJ, Kluger HM, Shuch B. PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma? J Clin Pathol 2015;68:12-7.
10. Al-Ahmadie HA, Alden D, Qin LX, et al. Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. Am J Surg Pathol 2008;32:377-82.
11. Xiao X, Hu R, Deng FM, Shen SS, Yang XJ, Wu CL. Practical applications of immunohistochemistry in the diagnosis of genitourinary tumors. Arch Pathol Lab Med 2017;141:1181-94.
12. Reuter VE, Argani P, Zhou M, Delahunt B. Best practices recommendations in the application of immunohistochemistry in the kidney tumors: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol 2014;38(8):e35-e49.
13. Kawakami A, Fisher DE. The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. Lab Invest 2017;97:649-56.
14. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs. Part A. Renal, penile, and testicular tumours. Eur Urol 2016;70:93-105.
15. Argani P. MiT family translocation renal cell carcinoma. Semin Diagn Pathol 2015;32:103-13.
16. Argani P, Olgac S, Tickoo SK, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol 2007;31:1149-60.
17. Smith NE, Illei PB, Allaf M, et al. t(6;11) Renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases. Am J Surg Pathol 2014;38:604-14.
18. Argani P, Yonescu R, Morsberger L, et al. Molecular confirmation of t(6;11) (p21;q12) renal cell carcinoma in archival paraffin-embedded material using a breakapart TFEB FISH assay expands its clinicopathologic spectrum. Am J Surg Pathol 2012;36:1516-26.
19. Argani P, Ladanyi M. Translocation carcinomas of the kidney. Clin Lab Med 2005;25:363-78.
20. Geller JI, Argani P, Adeniran A, et al. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer 2008;112:1607-16.
21. Hintzy MC, Camparo P, Vasiliu V, Peyromaure M, Vieillefond A. Renal carcinoma associated with MiTF/TFE translocation: report of six cases in young adults. Prog Urol 2008;18:275-80. (In French.)
22. Kuroda N, Tanaka A, Sasaki N, et al. Review of renal carcinoma with t(6;11) (p21;q12) with focus on clinical and pathobiological aspects. Histol Histopathol 2013;28:685-90.
23. Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomized, phase 3 trial. Lancet 2016;387:2008-16.
24. Motzer RJ, Haas NB, Donskov F, et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol 2017;35:3916-23.
25. Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 2016;375:2246-54.

Copyright Â© 2018 Massachusetts Medical Society.